News

Postmenopausal women may significantly lower their risk of fractures with a simple and cost-effective treatment: infrequent IV infusions of zoledronate (Reclast). Research published in the New England Journal of Medicine reveals the long-term benefits of this bone-strengthening drug in reducing fractures among women in the early stages of menopause.

Key Findings

A study led by Dr. Mark Bolland, an associate professor of medicine at the University of Auckland, New Zealand, revealed that women aged 50 to 60 who received two infusions of zoledronate over five years experienced a:

- 44 per cent reduction in spinal fractures,

- 40 per cent decrease in major osteoporosis-related fractures, and

- 28 per cent lower risk of fragility fractures, which often result from minimal trauma, such as a minor fall.

The treatment’s simplicity and affordability make it a viable option for millions of women. Zoledronate is a generic drug, and its infrequent administration—once every five years—minimizes costs and potential side effects.

The Risk of Fractures in Postmenopausal WomenPostmenopausal women face a 50 per cent lifetime risk of fractures due to age-related bone thinning and frailty. As estrogen levels drop during menopause, bone density decreases, increasing the likelihood of breaks. While zoledronate has long been used to treat osteoporosis, its effectiveness as a preventive measure in women with normal or near-normal bone density has not been fully explored until now.

Study Design

The trial involved over 1,000 women, with an average age of 56, who were randomly assigned to receive either two IV infusions of zoledronate or a placebo. The first dose was administered at the start of the study, and the second five years later. Over the course of 10 years, researchers monitored the participants for fractures and bone health.

Women who received zoledronate demonstrated significantly better outcomes than those on the placebo. Beyond reducing spinal and major fractures, zoledronate also lowered the risk of any fracture by 30 per cent, emphasizing its potential as a preventative treatment for bone health in early postmenopause.

A New Approach to Fracture Prevention

Dr. Bolland and his team suggest that postmenopausal women concerned about fractures consider zoledronate infusions every five to ten years. This low-frequency regimen offers a practical solution for preventing bone loss without the burden of frequent treatments.

Dr. Roland Chapurlat, chief of rheumatology and bone diseases at Edouard Herriot Hospital in Lyon, France, echoed this sentiment in an editorial accompanying the study. He described infrequent zoledronate doses as “a real opportunity” for women to proactively protect their bone health.

Supporting Bone Health

While zoledronate offers a significant advantage, maintaining strong bones requires a holistic approach, including:

- Adequate calcium and vitamin D intake to support bone density,

- Regular weight-bearing exercises like walking or resistance training,

- Avoiding smoking and excessive alcohol consumption, which weaken bones, and

- Routine bone density screenings to monitor bone health over time.

Get Latest News Live on Times Now along with Breaking News and Top Headlines from Health and around the world.